Background Smoking cessation is important in patients with tuberculosis because it can
reduce the high rates of treatment failure and mortality. We aimed to assess the …

Background and aims Tuberculosis (TB) patients who quit smoking have much better
disease outcomes than those who continue to smoke. In general populations, behavioural …

Background Smokers need effective support to maximise the chances of successful quit
attempts. Current smoking cessation medications, such as nicotine replacement therapy …

Background and aims Smoking is considered the main cause of preventable death world‐
wide. This study aimed to review the efficacy and safety of cytisine for smoking cessation …

Background Cytisine, a partial agonist that binds with high affinity to the α4β2 nicotinic
acetylcholine receptor, is a low-cost treatment that may be effective in aiding smoking …

Background A recent rigorous study has shown that cytisine, a low-cost drug, is effective for
smoking cessation. A number of earlier studies exist, mostly from former communist …

Background Cytisine is a smoking cessation medication. This systematic review
incorporates recently published randomized controlled trials (RCTs) to provide an updated …

Background Placebo-controlled trials indicate that cytisine, a partial agonist that binds the
nicotinic acetylcholine receptor and is used for smoking cessation, almost doubles the …

Nearly 50 years ago, and before any smoking cessation aids were approved in the Western
world, cytisine was being used in eastern and central Europe to help people quit smoking …

Objectives: Cytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking
cessation for 40 years. Cytisine is a partial agonist with high affinity binding to the α4β2 …